Two points worth noting: i) No cash is changing hands immediately; and ii) PFE shareholders may end up with shares of the consumer-health JV at some point.
Currently, the consumer-health (i.e. OTC) segment comprises 25% of GSK's overall sales and 7% of PFE's overall sales.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.